Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib added to standard treatment for non-muscle invasive bladder transitional cell carcinoma
ISRCTN84681538Phase 3Completed
- Sponsor
- The Institute of Cancer Research
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in bladder cancer and transitional cell carcinoma (TCC) comparing Celecoxib plus standard treatment with Placebo plus standard treatment (2 arms). Primary endpoint: Recurrence-free survival of bladder transitional cell carcinoma at 3 years. Started May 2006; status: completed.
02
Drugs
celecoxib
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ISRCTN84681538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN84681538.